Small-cell lung cancer articles within Nature Medicine

Featured

• Article
  14 September 2023 | Open Access

  Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial

  The combination of a bispecific antibody against EGFR and MET with a tyrosine kinase inhibitor (TKI) in patients with TKI-relapsed, chemotherapy-naive, EGFR-mutated advanced NSCLC is safe and shows preliminary efficacy.

  • Byoung Chul Cho
  • , Dong-Wan Kim
  •  & Keunchil Park

• Article | 13 January 2022

  Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication

  The combination of anti-GD2 and CD47 blockade mediates robust anti-tumor activity in mouse models of neuroblastoma, osteosarcoma and small-cell lung cancer by reorienting macrophage activity toward tumor cell phagocytosis.

  • Johanna Theruvath
  • , Marie Menard
  •  & Robbie G. Majzner

• Letter | 05 March 2018

  SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors

  Genomic and drug screens identify SHP2 blockade as a therapeutic approach for ALK-rearranged non-small cell lung cancers developing resistance through ALK-mutant-independent mechanisms.

  • Leila Dardaei
  • , Hui Qin Wang
  •  & Jeffrey A Engelman

• Letter | 21 November 2016

  Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer

  Copy-number alterations detected in circulating tumor cells at time of diagnosis predict chemosensitive versus chemorefractory responses; however, CTCs obtained after subsequent relapse bear a chemosensitive copy-number alteration profile, which suggests that different mechanisms drive initial and acquired chemoresistance.

  • Louise Carter
  • , Dominic G Rothwell
  •  & Ged Brady

• Article | 01 June 2014

  Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer

  Circulating tumor cells from patients with small-cell lung cancer can form tumors in mice, and their derived explants recapitulate the patients' response to chemotherapy.

  • Cassandra L Hodgkinson
  • , Christopher J Morrow
  •  & Caroline Dive

• Letter | 09 October 2011

  A crucial requirement for Hedgehog signaling in small cell lung cancer

  The authors find that cell-intrinsic activation of Hedgehog signaling without genetic alterations is a contributing feature to the progression and chemotherapy resistance of small-cell lung carcinoma, and that Hedgehog inhibition can prevent lung cancer growth and recurrence.

  • Kwon-Sik Park
  • , Luciano G Martelotto
  •  & Julien Sage